Research Analysts Offer Predictions for MAZE Q3 Earnings

Key Points

• Leerink Partners has lowered its Q3 2025 EPS forecast for Maze Therapeutics to (0.81), compared to the previous estimate of (0.79).
• The company reported quarterly earnings of (0.77) EPS, beating consensus estimates by $0.02, indicating a positive performance despite the lowered forecast.
• Overall, the stock has an average rating of "Buy" with a consensus price target of $25.60, suggesting optimistic expectations from analysts despite recent revisions.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) - Research analysts at Leerink Partnrs decreased their Q3 2025 earnings per share (EPS) estimates for Maze Therapeutics in a report issued on Wednesday, August 13th. Leerink Partnrs analyst J. Schwartz now forecasts that the company will post earnings of ($0.81) per share for the quarter, down from their prior estimate of ($0.79). Leerink Partnrs also issued estimates for Maze Therapeutics' Q4 2025 earnings at ($0.82) EPS, FY2025 earnings at ($3.54) EPS, Q1 2026 earnings at ($0.82) EPS, Q2 2026 earnings at ($0.82) EPS, Q3 2026 earnings at ($0.82) EPS, Q4 2026 earnings at ($0.82) EPS, FY2026 earnings at ($3.28) EPS and FY2027 earnings at ($2.60) EPS.

A number of other analysts have also recently commented on the company. Wedbush started coverage on Maze Therapeutics in a research report on Tuesday, July 8th. They issued an "outperform" rating and a $17.00 price objective for the company. Wall Street Zen upgraded Maze Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. Finally, HC Wainwright initiated coverage on Maze Therapeutics in a research note on Wednesday, July 23rd. They issued a "buy" rating and a $34.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and five have assigned a Buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $25.60.

Maze Therapeutics Stock Up 2.0%

Shares of Maze Therapeutics stock traded up $0.26 on Monday, reaching $13.49. The company's stock had a trading volume of 263,956 shares, compared to its average volume of 172,630. Maze Therapeutics has a 52-week low of $6.71 and a 52-week high of $19.19. The stock has a 50-day moving average price of $13.96 and a 200-day moving average price of $11.85.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.79) by $0.02.

Institutional Trading of Maze Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE lifted its holdings in shares of Maze Therapeutics by 33.6% in the 2nd quarter. Bank of America Corp DE now owns 5,782 shares of the company's stock valued at $71,000 after buying an additional 1,455 shares during the period. CWM LLC acquired a new position in Maze Therapeutics during the second quarter worth $28,000. New York State Common Retirement Fund acquired a new position in shares of Maze Therapeutics in the first quarter worth $25,000. Legal & General Group Plc raised its holdings in shares of Maze Therapeutics by 387.0% in the second quarter. Legal & General Group Plc now owns 4,242 shares of the company's stock worth $52,000 after acquiring an additional 3,371 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Maze Therapeutics by 452.5% in the second quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company's stock worth $57,000 after acquiring an additional 3,774 shares during the last quarter.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.